ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
In Vivo Direct Reprogramming: Current Progress and Future Prospects from Mechanisms to Therapeutic Application.
Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Direct reprogramming, which converts somatic cells from one lineage to another without passing through a pluripotent state, represents a promising therapeutic strategy for regenerative medicine. Recent advancements in identifying reprogramming factors and understanding molecular barriers have enabled efficient generation of therapeutically relevant cells. Yet, the clinical application of in vitro-derived reprogrammed cells is hampered by the immature phenotype, hostile microenvironments, low engraftment, and poor survival after transplantation. In vivo direct reprogramming of tissue-resident cells within their native tissue microenvironment offers a compelling alternative to overcome these barriers. Harnessing biochemical and biophysical cues of the tissue microenvironment, this approach facilitates the acquisition of molecular and functional features resembling endogenous cells. This review summarizes the current understanding of in vivo direct reprogramming, covering mechanisms, key reprogramming factors, and delivery strategies, and explores therapeutic applications across organ systems. Finally, key challenges such as delivery efficiency, incomplete understanding of tissue cues, and limited mechanistic insights, along with emerging strategies, are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.